Wolfspeed sued Navitas and three affiliates in Delaware court, alleging infringement of multiple GaN and SiC patents used in EV and power‑conversion gear.

At 50, SAS is publicly mapping an AI-first strategy while executives say they've prepped systems for a potential IPO — but founder Jim Goodnight still calls the timing.

The FDA tapped seven companies — including Eli Lilly and Regeneron — for a PreCheck pilot to speed reviews of new U.S. drug plants. The cohort includes big pharma and specialized CDMOs.

Durham-based Wolfspeed has dropped its federal breach‑of‑contract suit against Jaguar Land Rover over a failed silicon‑carbide supply agreement. Public details and any settlement terms were not disclosed.

Mary‑Dell Chilton, the NC biochemist who helped create the first genetically modified plants, died at 87 in Carrboro. Her work underpins modern crop biotechnology.

Duke and other labs are testing drugs and mitochondrial therapies that could ease chronic pain without sparking opioid addiction.

Duke researchers say a catheter‑delivered gene therapy restored pumping power and cut arrhythmias in lab‑grown heart tissue and monkeys, suggesting a possible one‑shot treatment for heart‑attack damage.

Asensus Surgical plans phased cuts of 108 employees at its Morrisville facility beginning Aug. 15; the company called the move an organizational realignment.

Altaris will buy RTP‑based Simulations Plus for about $375M, taking the drug‑development software company private while pledging to keep its headquarters in the Triangle.

Raleigh advisory firm Opex bought Dallas-based Intellys and says it will expand rapidly — including plans to roughly double its size — as it builds a national technology-advisory platform.

Red Hat and IBM launched Project Lightwell, a $5B initiative pairing AI and thousands of engineers to hunt and patch open-source vulnerabilities. The effort spotlights Raleigh's tech role.

N.C. A&T won approval to offer a Ph.D. in bioengineering — the first standalone doctorate of its kind at an HBCU — as the university pushes toward Carnegie R1 status.

A Duke-led study suggests bedside retinal scans of very preterm infants may predict motor and cognitive delays by age two.